Some limitations of our study were: 1) the sample size was relatively low (N=176), thus there might be a relatively low statistical power; 2) the follow-up duration (median: 17.0 months (range 1.0 to 47.0 months)) was relatively short, therefore the predictive value of KIF2A in long-term treatment outcomes was not assessed; 3) as a single-center study, this study might lack wide representativeness; and 4) therapeutic approaches for AML patients with high KIF2A expression were not suggested in this primary research. This evidence concerns the gene KIF2A and acute myeloid leukemia.